EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study

Eleonora M Vromen, Sterre C M de Boer, Charlotte E Teunissen, Annemieke Rozemuller, Anne Sieben, Maria Bjerke, Alzheimer’s Disease Neuroimaging Initiative, Pieter Jelle Visser, Femke H Bouwman, Sebastiaan Engelborghs iD, Betty M Tijms iD

Brain · 01.03.2023 · 146 (3) · 1166-1174

DOI: 10.1093/brain/awac158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 02.05.2022. Verfasst von Eleonora M Vromen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Center Amsterdam, Amsterdam Neuroscience, VUMC, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, ZonMW Memorabel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The biological definition of Alzheimer’s disease using CSF biomarkers requires abnormal levels of both amyloid (A) and tau (T). However, biomarkers and corresponding cutoffs may not always reflect the presence or absence of pathology. Previous studies suggest that up to 32% of individuals with autopsy-confirmed Alzheimer’s disease show normal CSF p-tau levels in vivo, but these studies are sparse and had small sample sizes. Therefore, in three independent autopsy cohorts, we studied whether or not CSF A+T− excluded Alzheimer’s disease based on autopsy. We included 215 individuals, for whom ante-mortem CSF collection and autopsy had been performed, from three cohorts: (i) the Amsterdam Dementia Cohort (ADC) [n = 80, 37 (46%) Alzheimer’s disease at autopsy, time between CSF collection and death 4.5 ± 2.9 years]; (ii) the Antwerp Dementia Cohort (DEM) [n = 92, 84 (91%) Alzheimer’s disease at autopsy, time CSF collection to death 1.7 ± 2.3 years]; and (iii) the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [n = 43, 31 (72%) Alzheimer’s disease at autopsy, time CSF collection to death 5.1 ± 2.5 years]. Biomarker profiles were based on dichotomized CSF Aβ1-42 and p-tau levels. The accuracy of CSF AT profiles to detect autopsy-confirmed Alzheimer’s disease was assessed. Lastly, we investigated whether the concordance of AT profiles with autopsy diagnosis improved when CSF was collected closer to death in 9 (10%) DEM and 30 (70%) ADNI individuals with repeated CSF measurements available. In total, 50–73% of A+T− individuals and 100% of A+T+ individuals had Alzheimer’s disease at autopsy. Amyloid status showed the highest accuracy to detect autopsy-confirmed Alzheimer’s disease (accuracy, sensitivity and specificity in the ADC: 88%, 92% and 84%; in the DEM: 87%, 94% and 12%; and in the ADNI cohort: 86%, 90% and 75%, respectively). The addition of CSF p-tau did not further improve these estimates. We observed no differences in demographics or degree of Alzheimer’s disease neuropathology between A+T− and A+T+ individuals with autopsy-confirmed Alzheimer’s disease. All individuals with repeated CSF measurements remained stable in Aβ1-42 status during follow-up. None of the Alzheimer’s disease individuals with a normal p-tau status changed to abnormal; however, four (44%) DEM individuals and two (7%) ADNI individuals changed from abnormal to normal p-tau status over time, and all had Alzheimer’s disease at autopsy. In summary, we found that up to 73% of A+T− individuals had Alzheimer’s disease at autopsy. This should be taken into account in both research and clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAmyloid beta-Peptidestau ProteinsBiomarkersSensitivity and SpecificityPeptide Fragments

Stichwörter der Autor:innen

AT(N)Alzheimer’s diseaseCSFautopsybiomarker

Substanzen

Amyloid beta-Peptidestau ProteinsBiomarkersPeptide Fragments

Autor:innen und Institutionen

  • Alzheimer Center Amsterdam, Amsterdam Neuroscience, VUMC, Amsterdam, The Netherlands.
  • Department of Neurodegeneration, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Department of Clinical Chemistry, Neurochemistry Lab and Biobank, Amsterdam Neuroscience, VUMC, Amsterdam, The Netherlands.
  • Department of Pathology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands.
  • Institute Born-Bunge, University of Antwerp, Wilrijk, Belgium.
  • Clinical Neurochemistry Laboratory, Department of Clinical Biology, Universitair Ziekenhuis Brussel and Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.

ORCID-Profile: Sebastiaan Engelborghs, Betty M Tijms

Förderung

  • NIA NIH HHS
  • ZonMW Memorabel

Zitieren

APA

Vromen, E. M., de Boer, S. C. M., Teunissen, C. E., Rozemuller, A., Sieben, A., Bjerke, M., Alzheimer’s Disease Neuroimaging Initiative, Visser, P. J., Bouwman, F. H., Engelborghs, S., & Tijms, B. M. (2023). Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study. Brain, 146(3), 1166-1174. https://doi.org/10.1093/brain/awac158

Vancouver

Vromen EM, de Boer SCM, Teunissen CE, Rozemuller A, Sieben A, Bjerke M, et al. Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study. Brain. 2023;146(3):1166-1174. doi:10.1093/brain/awac158

BibTeX
@article{Vromen2023,
  author = {Vromen, Eleonora M and de Boer, Sterre C M and Teunissen, Charlotte E and Rozemuller, Annemieke and Sieben, Anne and Bjerke, Maria and Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Neuroimaging Initiative and Visser, Pieter Jelle and Bouwman, Femke H and Engelborghs, Sebastiaan and Tijms, Betty M},
  title = {Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {3},
  pages = {1166--1174},
  doi = {10.1093/brain/awac158}
}
Kostenlos starten →